ArticleThe oncologist2018
Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?
Article in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Diversity in randomized clinical trials for peripheral artery disease: a systematic review.International journal for equity in health · 2024Pooled it
- Factors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United States.Frontiers in oncology · 2026Article
- Implementation of a Patient Navigation Program to Support Representative Participation in Cancer Clinical Trials.Cancer medicine · 2025Article
- Promoting Racial Justice in Cancer Clinical Trials: Community Engaged Solutions for Bridging Gaps.Cancer medicine · 2025Article
- Article
- Exploring Biologic Treatment Hesitancy Among Black and Indigenous Populations in Canada: a Review.Journal of racial and ethnic health disparities · 2023Review
- Article
- Barriers and strategies for recruiting participants who identify as racial minorities in musculoskeletal health research: a scoping review.Frontiers in public health · 2023Article
- Prostate cancer screening in Black men in Canada: a case for risk-stratified care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Article
- Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study.JMIR cancer · 2021Article
- The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.International journal of environmental research and public health · 2021Article
- Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database.Journal of neuro-oncology · 2020Article
- An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.Cancer research · 2019Review
- Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?Annual review of pharmacology and toxicology · 2019Review
- Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.Clinical pharmacology and therapeutics · 2018Article
- Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine.Cancer journal (Sudbury, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many approved drugs demonstrate different pharmacokinetics, pharmacodynamics, and/or safety across racial and ethnic groups. The primary objective of the current study was to summarize the racial and ethnic makeup of cancer clinical drug trials using cancer drugs approved by the U.S. Food and Drug Administration (FDA) between January 1, 2010, and July 31, 2016. In clinical studies used for FDA approvals, 82.3% of participants identified as white, 10.2% as Asian, 2.3% as black, and 4.7% as Hispanic. Black participants made up 7.7% of U.S. and Canadian cancer clinical drug trials and 2.6% of global cancer clinical drug trials while Asian participants made up 13.5% of global cancer clinical drug trials but only 1.8% of U.S. and Canadian cancer clinical drug trials. The current study indicates that although cancer clinical drug trials have become more inclusive of Asian participants, other racial and ethnic minority groups remain under-represented. This may result in an inadequate understanding of drug safety and efficacy in many racial and ethnic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.